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Part A: Abstract 
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Introduction 
Coagulation abnormalities are well described in patients with elevated levels of urea 
and/or creatinine secondary to renal failure. These range from hypercoagulable to 
hypocoagulable states due to a range of mechanisms well described in the literature. 
Conventional tests of coagulation such as INR and PTT do not adequately assess these 
disorders of coagulation. Thromboelastography (TEG®) has proven to be a suitable 
alternative test of coagulation that serves as a dynamic test of global coagulation 
including assessment of thrombus formation as well as its breakdown. TEG® and 
ROTEM® assesses the visco-elastic properties of blood in vitro to define in vivo 
coagulability. The standard of care in our institution to assess the bleeding risk in 
patients with renal failure (defined by a raised urea and/or creatinine level) presenting 
for a renal biopsy is to use the conventional tests of coagulation, including a bleeding 
time if their creatinine is above 300 µmol/L. The aim of this study is to evaluate the 
conventional standard laboratory tests of coagulation (including a bleeding time where 
available), TEG® and ROTEM® in assessing coagulation disorders in patients with 
elevated levels of urea and/or creatinine presenting for renal biopsy. 
 
Methodology 
Patients with elevated levels of urea and/or creatinine presenting for a renal biopsy will 
be identified by the nephrology team responsible for their medical management. Prior to 
the renal biopsy, these patients will be approached by the study team and reviewed for 
inclusion into the study. Informed consent will be obtained on agreement to participate 
in the study. We will collect a blood sample for the TEG® and ROTEM® and this test will 
be performed by a laboratory technician in the Department of Anaesthesia. The 
clinician/nephrologist performing the biopsy will not be influenced by the outcome of 
these viscoelastic tests. A convenience sample of a minimum of 25 patients with renal 
impairment presenting for a renal biopsy will be included in this study. 
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Results 
A total of 44 adult participants was entered into this observational study. Results for 1 
participant were excluded from this study as their biopsy was delayed, allowing their 
renal function to improve and return to normal with medical management on the day 
that they presented for a renal biopsy. 43 patients were worked up for a renal biopsy but 
only 38 patients proceeded to a renal biopsy. Of these, only 31 patients had a bleeding 
time performed on the day of their renal biopsy. The participants ages ranged from 24 to 
69 years and included 24 male and 19 female participants. Renal biopsies were 
cancelled by the consultant nephrologist in 5 patients on the day of their biopsy. Control 
samples, from 10 members in the Department of Anaesthesia, fell within the specified 
range of the various manufacturers. An interesting TEG® result was an average MA 
result of 74.22 mm (normal range 64 – 72 mm), which lies above the upper limit of 
normal. Two patients developed a small renal haematoma on ultrasound after the 
biopsy, with 1 of these patients also developing haematuria. 
 
Conclusion 
TEG® and ROTEM® provides a global assessment of coagulation and might be helpful 
in assessing coagulation defects in patients with elevated levels of urea and/or 
creatinine presenting for a renal biopsy, with possible extension to the surgical patient 
with abnormal renal function presenting for a surgical procedure to assess their risk of 
bleeding, especially in those who are being considered for a regional or neuraxial 
technique - as this could be an unacceptable risk in this population sub-group . 
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Part B: Study proposal 
As approved by the Departmental Research Committee (Addendum A) and the Human 
Research Ethics Committee of the University of Cape Town (Addendum B). 
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Background: 
It is well known that patients with renal impairment, either with acute kidney injury (AKI) 
or chronic kidney disease (CKD) have high levels of urea and other nitrogenous waste 
products circulating in their blood (Berns & Coutre, 2015; Soyoral et al., 2012; 
Stammers, Bruda, Gonano, & Hartmann, 1998). The range of coagulation 
abnormalities, from hypercoagulable to hypocoagulable states, due to several 
mechanisms (Boccardo, Remuzzi, & Galbusera, 2004) are well described in the 
literature (Berns & Coutre, 2015; Boccardo et al., 2004; Kaw & Malhotra, 2006; Soyoral 
et al., 2012; Stammers et al., 1998). Patients with renal impairment “may experience 
two opposite haemostatic complications: bleeding diathesis and thrombotic tendencies” 
(Boccardo et al., 2004). Bleeding may range from an insignificant bleed (such as 
purpura) to a serious gastro-intestinal haemorrhage complicating either AKI or CKD. 
With the introduction of dialysis and erythropoietin, bleeding complications have 
decreased (Berns & Coutre, 2015; Boccardo et al., 2004); however, it still impacts on 
clinical decision making. These patients can present for surgery and can be a challenge 
to the anaesthesiologist when considering possible interventions. 
Conventional tests of coagulation (e.g. bleeding time (BT), INR, PTT) assesses 
components of the coagulation cascade (Slaughter, 2010); however, they do not 
adequately assess coagulation abnormalities. Furthermore, they are purely plasma-
based tests and thus provide no information on the cell-based aspects of coagulation. 
These tests thus provide only isolated information on individual components of the 
coagulation cascade. Thromboelastography (TEG®) and rotational thromboelastometry 
(ROTEM®) have been shown to be suitable ex-vivo tests, serving as dynamic measures 
of in vivo coagulation. TEG® is a visco-elastic measure of coagulation and provides a 
global assessment of whole blood thrombus formation, stabilisation and fibrinolysis that 
reflects in vivo haemostasis. ROTEM® is a modification of the thromboelastogram. 
These tests provide the clinician with information on the “coagulation cascade, 
fibrinogen and the platelets” and their interaction “as an entire unit” (Timmermans, 
Dolmans, & Kahn, 2009) and can guide the replacement of blood and blood 
components in the surgical patient (Johansson, Bochsen, Stensballe, & Secher, 2008). 
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TEG® is generally performed on a single channel that is activated with a contact agent 
such as celite or diatomaceous earth. ROTEM® routine provides 4 channels: 
coagulation is stimulated with recombinant tissue factor (similar to the INR, but with 
cellular elements) called the EXTEM, ellagic acid (similar to the aPTT) called the 
INTEM, tissue factor plus cytochalasin to remove platelet components and assess the 
fibrinogen component only (FIBTEM), whilst the 4th channel can be used with 
heparinase or aprotonin to remove the effects of heparin or fibrinolysis (see below). 
Thus, ROTEM® may provide more information than TEG® alone, specifically with regard 
to the contribution of fibrinogen. 
TEG® was first described by Hartert in 1948 (Stammers et al., 1998; Whiting & DiNardo, 
2014) as a device that provided information about the nature of whole-blood 
haemostasis, thrombus strength and its breakdown. It provides information on both 
cellular and non-cellular factors involved in thrombus formation. This point of care 
system assesses the visco-elastic properties of blood being tested and provided a 
global assessment of coagulation (Curry & Pierce, 2007). 
In this study, we will evaluate the ability of coagulation parameters of 
thromboelastography and rotational thromboelastometry to identify coagulation 
abnormalities in patients with elevated levels of urea and/or creatinine secondary to 
renal failure, presenting for a renal biopsy. We will also collect data concerning standard 
laboratory coagulation tests (e.g. INR, PTT, BT) but a statistical comparison between 
methods will not be performed. A convenience sample of a minimum of 25 patients 
presenting for a renal biopsy, will be tested in this observational case series. 
 
Methodology: 
Patients with elevated levels of urea and/or creatinine (renal impairment) presenting for 
work-up for a renal biopsy at Groote Schuur Hospital will be identified by the renal unit. 
Work-up for the renal biopsy includes a referral to the Renal Unit, the booking of a 
biopsy with the renal senior registrar, with a BT to be requested if the creatinine is > 300 
µmol/L. 
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On the day of biopsy, the current protocol regarding haematological criteria for eligibility 
for renal biopsy is (Addendum C): 
a platelet count ≥ 100 x 109/mL, 
PTT ˂ 40 seconds, 
INR ≤ 1.4, 
a bleeding time ≤ 10 min, or ≤ 12 min if an emergency biopsy. 
The TEG® and ROTEM® devices will be used as an alternative method of assessing the 
coagulation profile. This overcomes the technical difficulties of performing a bleeding 
time, as well as providing a more comprehensive in vitro assessment of coagulation. 
The primary outcome is thus to assess whole blood coagulation, using standard 
parameters generated by the TEG® and ROTEM® traces. In addition, fibrinogen 
concentrations (Wolberg & Campbell, 2008) will also be measured. 
A representative from the renal unit will inform the study group of patients on the day of 
the planned renal biopsy. Research participants will include both male and female adult 
subjects (age > 18) of any ethnicity with elevated levels of urea and/or creatinine 
presenting for a renal biopsy. These patients will be approached by a representative 
from the study group and included into the study only once informed consent 
(Addendum D) has been granted and prior to the provision of any sedation. Exclusion 
criteria included patient refusal, LMWH/heparin therapy, antiplatelet medication and 
renal replacement therapy. 
Blood sampling will be standardised between the phlebotomists, the blood specimen is 
to be taken using a Vacutainer (BD Vacutainer Systems, Plymouth, England). Blood 
sampling will be in accordance with accepted aseptic principles and technique. After the 
initial 3 mL of blood is discarded, the whole-blood sample is to be collected in a 2 mL 
syringe and dispatched to the Anaesthesia laboratory immediately, a further 2 samples 
will be collected in two 4 mL Greiner 9 NC Coagulation Sodium Citrate 3.2% tubes (BD 
Vacutainer) – 1 sample for the laboratory (NHLS) for fibrinogen testing and the other 
sample to the Anaesthesia laboratory as a control sample. The TEG® is to be measured 
on the TEG® 5000 Thromboelastograph Haemostasis Analyser System (Haemoscope) 
made available to us in the laboratory of the Department of Anaesthesia. ROTEM® will 
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be performed and analysed on the Viking ROTEM® Delta haemostasis analyser. The 
software for TEG® analysis will be performed on TEG®V4.2.3. For TEG®, measurement 
of R-time (reaction time), K-time (kinetics), maximum amplitude (MA) and coagulation 
index (CI) is to be performed for each patient. 
Additional tests with ROTEM® will be performed for each patient, and will include 
clotting time, clot formation time, alpha angle and maximum clot firmness. These 
additional tests include INTEM (which essentially analyses the intrinsic pathway), 
EXTEM (analysing the extrinsic pathway), FIBTEM (the addition of a platelet inhibitor 
prevents platelets from contributing to thrombus formation thus allowing analyses of the 
functional fibrinogen component) and APTEM (addition of aprotinin to inhibit 
fibrinolysis). 
TEG® and ROTEM® will be performed by the same laboratory technologist, to ensure 
standardisation of the test procedure. 
Statistical analysis will be performed using a standard statistical package (Statistica 
Version 13, Dell Inc, Tulsa, OK) and data will be evaluated in terms of means, medians, 
standard deviations and ranges. These measures will be compared with the standard 
ranges for conventional tests of coagulation, quoted by the instrument manufacturer, to 
identify possible coagulation abnormalities in this patient group. 
 
Referencing and Guidelines: 
The SAMJ author and referencing guidelines have been used as a guideline for this 
document, however, the references for Part B, C and D are in the APA 6th style. Once 
the manuscript is presented for publication, the references will be updated to the 
Vancouver style as specified by the SAMJ. Where a reference has a digital object 
identifier (DOI) available, these have been included. 
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Ethical Considerations: 
The study is approved by the Ethics Committee of the Faculty of Health Sciences of the 
University of Cape Town (Addendum B). 
Participation in the study will be voluntary, and participants will complete an informed 
consent form (Addendum D). 
Confidentiality and anonymity will be ensured. 
Participants will receive a participant number and be further identified throughout the 
study with the participant number (Addendum E and Addendum F). 
All data will be stored under the participant number (Addendum E and Addendum F). 
Participants are free to withdraw at any time and without providing a reason. 
All patients will receive the normal standard of care, irrespective of participation or non-
participation in the study (Addendum C). 
Participants will be ensured that they will be taking no extra risk if they agree to be part 
of the study. 
Participants will have no direct benefit from participation in the study, but participation 
will not hinder nor change the standard of care they will receive. 
There is to be no cost, nor compensation for participation in the study. 
Funding will be provided by the Department of Anaesthesia. 
No conflicts of interest have been identified or declared. 
The protocol complies with the Helsinki Declaration of 2008. 
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Objectives of the literature review 
The objectives of this literature review were to review the current published information 
about coagulation abnormalities in patients with elevated levels of urea and/or 
creatinine secondary to renal failure, and to include a short review of coagulation and 
the various tests of coagulation, pertinent to our study, which are currently available. 
The available literature frequently describes renal dysfunction and bleeding (or “uraemic 
bleeding”) and this predisposition to bleeding is often cited as being caused by an 
interference in platelet function (Boccardo et al., 2004; Soyoral et al., 2012). The 
association between renal dysfunction and bleeding has been known for more than 200 
years. “Patients with renal impairment are screened for bleeding risk by measuring the 
bleeding time” (Berns & Coutre, 2015), which is still the practice in our institution, prior 
to a renal biopsy or some other invasive procedure. 
 
Literature search strategy 
A literature search was performed using PubMed and the MeSH database. A search 
with the terms ‘uremia’ and ‘renal failure’ and ‘blood coagulation tests’ yielded 41 results 
(Addendum G) and a search with the terms ‘uremia’ and ‘renal failure’ and ‘blood 
coagulation’ yielded 52 results (Addendum H). Substituting ‘uraemia’ for ‘uremia’ yielded 
no further results. Filters included literature which was published between January 1970 
and December 2016, performed in humans and in English. Literature was excluded if it 
was not originally published in English. 
 
Review and critical appraisal of the literature 
Blood Coagulation 
No universally accepted definition of coagulation was found in the literature. A proposed 
definition for normal coagulation of blood (also known as clotting or haemostasis) 
denotes the biochemical sequence whereby blood changes from a liquid form into a gel-
like state, eventually resulting in the formation of a stable blood clot (a thrombus) and 
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the cessation of blood loss. Physiologically, this usually occurs due to the disruption of 
the integrity of the vascular endothelium and is initiated within seconds in an attempt to 
limit the loss of blood. 
Previously, haemostasis was separated into primary haemostasis, which was the 
formation of the platelet plug at the injury site, and secondary haemostasis, also 
known as the coagulation cascade. Secondary haemostasis was classically divided into 
three pathways: an extrinsic pathway (the tissue factor pathway), an intrinsic pathway 
(the contact activation pathway) and a final common pathway. This classic model of 
coagulation was grossly artificial and could explain haemostasis in vitro, however, it did 
not consider the interaction between primary and secondary haemostasis. The classic 
model aided the understanding of the pharmacology of anticoagulants and the 
interpretation of results of laboratory tests which assessed clotting times (e.g. 
prothrombin time, activated partial thromboplastin time and the INR), however this has 
been replaced with an updated model which was developed as our knowledge of 
coagulation improved. 
The classic model was an artificial interpretation of coagulation in vitro but did not 
accurately explain coagulation in vivo. In 2001, a cell-based model of coagulation 
was introduced by Maureane Hoffman and Dougald M. Monroe III (Hoffman & Monroe, 
2001). In this model, they proposed “that coagulation occurs not as a "cascade", but in 
three overlapping stages: 
1) Initiation, which occurs on a tissue factor (TF) bearing cell” (when TF binds to 
circulating factor VIIa, and in the presence of other factors leads to the generation of a 
small amount of thrombin); 
2) “Amplification, in which platelets and co-factors are activated to set the stage 
for large scale thrombin generation” (occurring on the surface of activated platelets); 
and 
3) “Propagation, in which large amounts of thrombin are generated on the 
platelet surface” (the thrombin burst). This currently accepted model of coagulation 
emphasises the pivotal role of TF-FVIIa complex, the importance of platelet activation 
and function, and the generation of thrombin in the promotion and inhibition of 
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coagulation (Curry & Pierce, 2007). Two further steps were identified to complete the 
model: 
4) “Stabilisation” (in which soluble monomers were crosslinked by FXIIIa to 
stabilise the thrombus) and  
5) “Inhibition of further coagulation” (to prevent the pathological extension of 
the thrombus and thus localising it to the area of injury. (Curry & Pierce, 2007) 
 
The Standard Tests of Coagulation 
For these tests to be adequately performed and accurately interpreted, standard 
guidelines on sampling techniques and blood collection must be adhered to. Poor 
sampling techniques may adversely affect the laboratory’s ability to accurately process 
the sample and provide accurate results. Whole blood specimens are collected in tubes 
to which a calcium-chelating agent (EDTA or citrate), in a 9:1 ratio of blood to 
anticoagulant, has been added to prevent the specimen from clotting. If the specimen 
tube is underfilled, the plasma volume of the specimen relative to the anticoagulant will 
be reduced and lead to impaired accuracy of the results obtained from these blood 
tests, resulting in falsely prolonged results. Routine tests of coagulation are typically 
performed on platelet poor plasma, which is prepared from whole citrated blood which 
has been centrifuged (Sultan, 2010). This action negates analysing the contribution of 
primary haemostasis to overall coagulation. 
 
Fibrinogen level 
The reference range is usually 2.0 – 4.0 g/L (but this is dependent on the laboratory and 
assay performed). Fibrinogen levels were performed on citrated blood by the local 
National Health Laboratory Service (NHLS). 
Several assays are currently available for the estimation of fibrinogen level. The NHLS 
utilises the Clauss assay (which is used by most laboratories) at present. According to 
Perry and Todd (2013), in this assay, plasma is diluted (usually 1:10) and then allowed 
to clot after exposure to a high concentration of thrombin. This test requires a reference 
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plasma where the level of fibrinogen is known, and which is calibrated against an 
international standard. A calibration curve is generated using the reference plasma in a 
series of dilutions and the results are plotted on graph paper. There should be a linear 
correlation between clotting times of the test and reference samples. The time taken for 
the test specimen to clot is compared to the calibration curve and the fibrinogen level 
can be deduced. 
 
Prothrombin Time (PT) 
This test was first described by Quick in 1935. It is the time required for fibrin strands to 
form in the sample after tissue factor, phospholipid and calcium has been added to the 
decalcified, platelet poor plasma. 
It measures the so-called extrinsic and common pathways in the classical model of 
coagulation and may be prolonged in deficiencies of fibrinogen, prothrombin; Factor (F) 
V, VII and X; DIC, vitamin K deficiency, liver disease and in patients receiving high 
doses of heparin. 
 
International Normalised Ratio (INR) 
This is the most sensitive test for a decrease in FVII, but it may also be affected by the 
factors which impair the PT. Initially, the term ‘thromboplastin’ was used for the 
substance that converted prothrombin to thrombin. Tissue thromboplastin was extracted 
from the brain and other organs and contained a significant amount of tissue factor and 
phospholipid. The different thromboplastins utilised in PT testing provide several ranges 
for PT; however, the INR uses a standardised thromboplastin reagent and “it is the ratio 
of the patient’s PT to a control PT” (Curry & Pierce, 2007), corrected for the sensitivity of 
the thromboplastin. 
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Activated Partial Thromboplastin Time (aPTT) 
This test measures the functioning of the intrinsic and common pathways of the classic 
model of coagulation. It is also performed on platelet poor plasma. The aPTT was 
described in 1953 and initially only the phospholipid concentration was controlled (as 
opposed to the phospholipid and surface activator concentrations), hence ‘partial 
thromboplastin’ (phospholipid is present, but there is no Tissue Factor). These 
phospholipid concentrations could accelerate clotting in normal plasma, but it did not 
correct clotting times for haemophilic plasma. Current automated aPTT testing utilises 
micronised silica and ellagic acid as a surface activator (these bind directly to FXII, 
causing its activation). Kaolin (which was historically used as the activator for this test) 
is no longer used as its opacity interferes with the optical detection of the endpoint. 
 
The Bleeding Time (BT) 
Perry and Todd (2013) described the BT as a tool to predict “the risk of bleeding in 
relation to surgery”. The BT is dependent on an adequate number of functional platelets 
and was thus developed to assess platelet function. The reference range is between 2 – 
7 minutes; however, this differs depending on the method used. Several methods have 
been developed, with the DUKE, the IVY and TEMPLATE methods being well 
described. 
The DUKE method (Duke, 1910) was described by the US pathologist William Waddell 
Duke (1883 – 1945), who was the first to conclusively demonstrate the role of platelets 
in haemostasis (Soyoral et al., 2012; Tocantins, 1946). This method was described by 
using a special needle to nick the earlobe. However, due to the high vascularity in this 
tissue, it is no longer used. 
The IVY method (a modification of the Duke Method by Ivy, Nelson and Bucher) (1941) 
is the traditional format of the test and utilises a blood pressure cuff inflated to 40 mmHg 
on the upper arm. A lancet or scalpel blade is used to make a stab wound on the palmar 
aspect of the forearm. The timer is then commenced, and every 30 seconds blood is 
drawn off with filter paper or paper towel, until the bleeding has stopped. The filter paper 
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can disturb the development of the platelet plug if it encounters the edge of the 
thrombus, so care should be exercised when blotting blood away. 
The TEMPLATE method was developed to standardise the IVY method and involves 
the same preparation, however, an automatic blade which can make a standard-sized 
incision (±6mm in length x 1mm in depth) on the palmar aspect of the forearm is 
utilised. 
The BT is not widely used due to difficulties in standardisation of the procedure, the 
wide variability of results and inter-operator differences; however, it is still routinely 
performed prior to an invasive procedure (e.g. renal biopsy) in patients with renal 
dysfunction. 
 
Viscoelastic Tests (TEG® and ROTEM®) 
The conventional laboratory tests of coagulation described above (e.g. PT, INR, aPTT, 
BT) assess components of the “classic coagulation cascade”; however, they do not 
adequately assess coagulation in its entirety. Although these tests provide valuable 
information, they can only provide isolated details on individual components, they have 
a longer turnaround time and require several millilitres of whole blood samples. The 
standard tests of coagulation need special preparation and highly trained staff and often 
have to be transported to a laboratory which may not be on-site. 
Near-patient or point-of-care testing has been documented since the English physician, 
Thomas Willis (27 January 1621 – 11 November 1675) described the tasting of the 
urine from a patient suspected of diabetes as a test for glycosuria (Hobbs, 1996). A 
point of care test (POCT) is defined by the International Organisation of Standardisation 
(ISO) as “testing that is performed near or at the site of the patient with the result 
leading to a possible change in the care of the patient”. “Near-patient test” is the 
preferred terminology used in the United Kingdom. These medical diagnostic tests 
provide reliable results faster than those processed through a laboratory, decreasing the 
turnaround time, ensuring that care is continued with the desired information readily 
available and capable of influencing rapid decision making (Delaney et al., 1999). 
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Thromboelastography (TEG®) has been shown to be a suitable near-patient ex vivo 
test, serving as a dynamic measure of coagulation. The TEG® was developed in 
Germany during World War II and was first described in the scientific literature by 
Professor Helmut Hartert, from the University of Heidelberg, in 1948. It is a visco-elastic 
measure of coagulation that provides a global assessment of whole blood thrombus 
formation, stabilisation and fibrinolysis which reflects in vivo haemostasis as well as 
providing information on both cellular and non-cellular components involved in thrombus 
formation. 
Rotational thromboelastometry (ROTEM®) was developed in 1997 by Andreas 
Calatzis (MD) and Pablo Fritzche (a physicist) as a modification and enhanced form of 
thromboelastography and is a worldwide TEG® competitor (Fritsma, 2015). These tests 
can provide the clinician with information about the “interaction of the coagulation 
cascade, fibrinogen and the platelets as an entire unit” (Timmermans et al., 2009) and 
be used to guide the replacement of blood and blood components in the surgical patient 
(Johansson et al., 2008). TEG® is utilised by both anaesthesiologists and surgeons to 
monitor coagulation factor deficiency, heparin therapy, platelet function and fibrinolysis 
in cardiac surgery, and over the last 20 years it has proven “vital to the management of 
coagulopathy secondary to shock and massive haemorrhage in trauma and surgery” 
(Fritsma, 2015). Limitations with TEG® include its susceptibility to vibrations and 
interferences with the surface the machine is placed on, whereas with ROTEM® these 
limitations are negated. 
TEG® and ROTEM® may be performed on fresh whole blood or on whole blood which 
has been collected in 3.2% sodium citrate specimen tubes. The TEG® sample volume is 
360µL and for ROTEM® it is 340µL. The TEG® can perform two assays at the same 
time, while ROTEM® can perform up to 6 additional tests (e.g. INTEM, EXTEM, 
FIBTEM, APTEM, HEPTAM and ECATEM). 
 
Renal Failure 
Renal failure can be divided into an ACUTE, CHRONIC or an ACUTE-ON-CHRONIC 
pathological process based on the patient’s history, presentation and the time frame of 
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the disease process. Much debate was previously encountered as to the precise 
definitions of these different entities. A lack of standardised definitions made it difficult to 
compare and interpret information obtained from different centres, and often spawned 
the generation of several guidelines targeting the same pathology. This practice was 
invariably driven by funding of professional societies worldwide by the pharmaceutical 
industry as a matter of self-interest. 
In an effort to standardise the definition of each pathological process, KDIGO (Kidney 
Disease: Improving Global Outcomes) was founded in 2003 “as an independently 
incorporated non-profit foundation governed by an international executive committee”. It 
was initially under management of the United States’ National Kidney Foundation 
(NKF). However, to facilitate its image as the developer of international guidelines 
targeting the global community, and not only the American populace, KDIGO obtained 
its status as an independent organisation under self-management on 01 October 2012. 
KDIGO is the sole international guideline organisation in nephrology and has published 
9 clinical practice guidelines to date, with two new guidelines under development. 
Their mission statement is to improve the management and outcomes of patients with 
renal disease by the development and implementation of evidence based clinical 
practice guidelines. 
In March 2012, KDIGO released its clinical practice guideline for ACUTE KIDNEY 
INJURY (AKI), defined as an abrupt decrease in kidney function. It is a clinical 
syndrome which encompasses several aetiologies. The definition and staging of AKI are 
based on RIFLE (Risk, Injury, Failure, Loss, End-stage Renal Disease) and AKIN 
(Acute Kidney Injury Network) criteria ("Kidney Disease: Improving Global Outcomes 
(KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute 
Kidney Injury," 2012). AKI is defined by the KDIGO criteria when any of the following are 
present: 
• Increase in SCr (serum creatinine) by ≥ 26.5µmol/l within 48 hours 
• Increase in SCr to ≥ 1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 days; or 
• Urine volume ≤ 0.5 ml/kg/h for 6 hours 
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and staged for severity (into stages 1, 2 or 3) based on the rise in SCr and 
reduction in urine output. Protocols have been developed for the 
identification of the cause of AKI and the management of this disease 
process. 
 
Chronic Kidney Disease (CKD), as defined by KDIGO, is the presence of abnormalities 
in kidney structure and function which are present for more than 3 months and has 
implications for health. It is classified according to the aetiology (based on the presence 
or absence of systemic disease and the location within the kidney), GFR category and 
albuminuria category. ("Kidney Disease: Improving Global Outcomes (KDIGO) CKD 
Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease.," 2013). 
 
The Effects of Uraemia on Coagulation 
Uraemia does not represent one single uraemic toxin but refers to several toxins (urea, 
creatinine, parathyroid hormone, β2 microglobulin, polyamines, advanced glycosylation 
end products, cyanate, phenols and other “middle molecules”) which become elevated 
in individuals with deteriorating renal function. This leads to a clinical syndrome 
associated with fluid and electrolyte abnormalities, hormonal imbalances and metabolic 
dysfunction. It is usually associated with the later stages of CKD, but it can occur if loss 
of renal function is rapid in AKI. A bleeding tendency has been described as 
characteristic in patients with end-stage renal disease, which is thought to be due to 
platelet dysfunction resulting in a disturbance in platelet adhesion and aggregation 
(Soyoral et al., 2012). However, anaemia, dialysis (due to the use of heparin during 
dialysis) and drug accumulation have also been identified as other plausible causes for 
the disturbance in haemostasis. Dialysis has been shown to only partly reverse the 
haemostatic disturbance caused by uraemic toxins. 
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The need for further research 
The exact mechanism by which the coagulation pathway, in a patient with elevated 
levels of urea and/or creatinine, is impaired remains to be identified and further research 
in this field is necessary. In our literature search we encountered numerous citations to 
the bleeding tendency which develops; however, less information regarding the 
hypercoagulable state is available. Even though patients with renal failure have 
potential for a range of coagulation abnormalities, these patients are often denied 
access to interventions due to the risk which the associated pathology introduces. 
These patients would benefit from having their coagulation monitored with 
thromboelastography, and where there is doubt regarding platelet function a platelet 
function analyser may be utilised. TEG® provides a global assessment of coagulation 
and may prove helpful in assessing coagulation defects in patients with elevated levels 
of urea and/or creatinine presenting for renal biopsy. The final decision rests with the 
attending physician who should practice discretion when ordering special investigations, 
to always question whether an invasive procedure is necessary and to search for the 
possibility of a non-invasive option. 
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Abstract: 
Introduction 
Coagulation abnormalities are well described in patients with elevated levels of urea 
and/or creatinine secondary to renal failure. These range from hypercoagulable to 
hypocoagulable states due to a range of mechanisms well described in the literature. 
Conventional tests of coagulation such as INR and PTT do not adequately assess these 
disorders of coagulation. Thromboelastography (TEG®) has proven to be a suitable 
alternative test of coagulation that serves as a dynamic test of global coagulation 
including assessment of thrombus formation as well as its breakdown. TEG® and 
ROTEM® assesses the visco-elastic properties of blood in vitro to define in vivo 
coagulability. The standard of care in our institution to assess the bleeding risk in 
patients with renal failure (defined by a raised urea and/or creatinine level) presenting 
for a renal biopsy is to use the conventional tests of coagulation, including a bleeding 
time if their creatinine is above 300 µmol/L. The aim of this study is to evaluate the 
conventional standard laboratory tests of coagulation (including a bleeding time where 
available), TEG® and ROTEM® in assessing coagulation disorders in patients with 
elevated levels of urea and/or creatinine presenting for renal biopsy. 
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Methodology 
Patients with elevated levels of urea and/or creatinine presenting for a renal biopsy will 
be identified by the nephrology team responsible for their medical management. Prior to 
the renal biopsy, these patients will be approached by the study team and reviewed for 
inclusion into the study. Informed consent will be obtained on agreement to participate 
in the study. We will collect a blood sample for the TEG® and ROTEM® and this test 
will be performed by a laboratory technician in the Department of Anaesthesia. The 
clinician/nephrologist performing the biopsy will not be influenced by the outcome of 
these viscoelastic tests. A convenience sample of a minimum of 25 patients with renal 
impairment presenting for a renal biopsy will be included in this study. 
Results 
A total of 44 adult participants was entered into this observational study. Results for 1 
participant were excluded from this study as their biopsy was delayed, allowing their 
renal function to improve and return to normal with medical management on the day 
that they presented for a renal biopsy. 43 patients were worked up for a renal biopsy but 
only 38 patients proceeded to a renal biopsy. Of these, only 31 patients had a bleeding 
time performed on the day of their renal biopsy. The participants ages ranged from 24 to 
69 years and included 24 male and 19 female participants. Renal biopsies were 
cancelled by the consultant nephrologist in 5 patients on the day of their biopsy. Control 
samples, from 10 members in the Department of Anaesthesia, fell within the specified 
range of the various manufacturers. An interesting TEG® result was an average MA 
result of 74.22 mm (normal range 64 – 72 mm), which lies above the upper limit of 
normal. Two patients developed a small renal haematoma on ultrasound after the 
biopsy, with 1 of these patients also developing haematuria. 
Conclusion 
TEG® and ROTEM® provides a global assessment of coagulation and might be helpful 
in assessing coagulation defects in patients with elevated levels of urea and/or 
creatinine presenting for a renal biopsy, with possible extension to the surgical patient 
with abnormal renal function presenting for a surgical procedure to assess their risk of 
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bleeding, especially in those who are being considered for a regional or neuraxial 
technique - as this could be an unacceptable risk in this population sub-group. 
 
Background: 
It is well known that patients with renal dysfunction (either Acute Kidney Injury (AKI), 
Chronic Kidney Disease (CKD) or acute-on-chronic kidney disease) have elevated 
levels of urea and other nitrogenous waste products circulating in their blood (Berns & 
Coutre, 2015; Soyoral et al., 2012; Stammers et al., 1998). The range of coagulation 
abnormalities from hypercoagulable to hypocoagulable states, due to several postulated 
mechanisms (possibly due to an imbalance in procoagulant and anticoagulant factors, 
platelet interaction in patients with elevated levels of urea, platelet-vessel wall 
interactions, platelet abnormalities, anaemia, thrombocytopaenia, drug interactions, or 
renal replacement therapy) (Boccardo et al., 2004), are well described in the literature 
(Berns & Coutre, 2015; Kaw & Malhotra, 2006; Soyoral et al., 2012; Stammers et al., 
1998). Patients with renal dysfunction may therefore “experience two opposite 
haemostatic complications: bleeding diatheses and thrombotic tendencies” (Boccardo et 
al., 2004). Bleeding may range from an insignificant bleed (such as purpura) to a 
serious gastro-intestinal haemorrhage complicating either AKI or CKD. With the 
introduction of dialysis and erythropoietin, bleeding complications have decreased 
(Berns & Coutre, 2015; Boccardo et al., 2004; Soyoral et al., 2012); however, it still 
impacts on clinical decision making and limits invasive procedures in renal failure 
patients. These patients can present to surgery and can be a challenge to the 
anaesthesiologist when considering possible interventions. 
Conventional tests of coagulation (e.g. INR, PTT, BT) assesses components of the 
coagulation cascade (Slaughter, 2010); however, they do not adequately assess 
coagulation abnormalities. These tests only provide isolated information on individual 
components of the coagulation cascade. 
Thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) have been 
shown to be suitable ex vivo tests, serving as dynamic measures of coagulation. TEG® 
and ROTEM® are visco-elastic measures of coagulation and provide a global 
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assessment of whole blood thrombus formation, stabilisation of the thrombus, as well as 
fibrinolysis - which reflects in vivo haemostasis. ROTEM® is a modification of 
thromboelastography. These tests provide the clinician with information on “the 
coagulation cascade, fibrinogen and the platelets” and their interaction “as an entire 
unit” (Timmermans et al., 2009) and can guide the replacement of blood and blood 
components in the surgical patient (Johansson et al., 2008). 
 
TEG® was first described by Hartert in 1948 (Stammers et al., 1998; Whiting & DiNardo, 
2014) as a device that provided information about the nature of whole-blood 
coagulation, the strength of the thrombus and its breakdown. It provided information on 
both cellular and non-cellular components involved in coagulation. This point of care 
system assesses the visco-elastic properties of blood being tested and provides a 
global assessment of coagulation (Curry & Pierce, 2007). The machine consists of a pin 
and oscillating cup (cuvette) (Stammers et al., 1998). 360 uL of whole blood is placed in 
a heated cup (at 37°C) and a pin is suspended from a torsion wire into the sample. The 
torsion wire is connected to a transducer and its movement is transduced and 
interpreted by a computer. The cup is subjected to oscillations through an angle of 4°45ʹ 
with the duration of each rotation cycle lasting 10 seconds. As the blood coagulates, 
fibrin strands form between the blood in the cup and the pin. The rotation of the cup is 
passed to the suspended pin, which in turn begins to rotate with the oscillating cup. A 
transducer, capable of sensing and amplifying these changes in the force, passes this 
information through a microprocessor to be interpreted and displayed by a computer as 
a TEG® profile. Specific patterns (Curry & Pierce, 2007; Whiting & DiNardo, 2014) are 
represented in Addendum I. 
 
ROTEM® (or TEM®) is an enhancement of TEG® and it provides a similar trace to that of 
TEG®, however different coagulation activators are utilised. Instead of the signal being 
transmitted via a torsion wire, with ROTEM® the signal from the pin is transmitted via an 
optical detector system. The cup (cuvette) remains immobile, while the pin slowly 
oscillates within the whole blood sample of 340µL, and as the thrombus forms the 
speed of oscillation of the pin decreases. The speed of oscillation of the pin is detected 
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by an optical detector system which utilises a light source and a mirror mounted on the 
pin. Additional tests with ROTEM® include: 
INTEM: Phospholipid and ellagic acid are added to the blood sample as 
activators. It is similar to the aPTT and thus essentially analyses the INTRINSIC 
pathway. It provides information on factor deficiencies and can detect the 
presence of anticoagulants. 
EXTEM: Tissue factor is added as the activator. The information provided by this 
test is similar to that obtained by Prothrombin Time. It essentially analyses the 
EXTRINSIC pathway. 
FIBTEM: Cytochalasin D (a platelet inhibitor) is used in this test together with 
tissue factor. The contribution of platelets to coagulation is thus removed. It is 
possible to analyse the functional FIBRINOGEN component only. 
APTEM: Aprotinin is added to the blood sample. It effectively inhibits fibrinolysis. 
HEPTEM: Heparinase is added which deactivates heparin. 
ECATEM: Ecarin is added to the sample. This test is a sensitive test to the 
presence of direct thrombin inhibitors. 
A typical ROTEM® trace for a normal individual is included in Addendum J. 
 
In this study, we attempted to evaluate the ability of coagulation parameters of the 
thromboelastograph (TEG®) and rotational thromboelastometry (ROTEM®) to identify 
coagulation abnormalities in patients with elevated levels of urea and/or creatinine 
secondary to renal failure, presenting for a renal biopsy. We also collected conventional 
coagulation tests (e.g. BT, INR, PTT) but statistical comparisons between these 
methods were not to be performed. A convenience sample of a minimum of 25 patients 
presenting for a renal biopsy, was to be tested in this observational case series. The 
primary endpoint was an observational study of the coagulation disorders present in this 
sample of patients. 
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Methodology: 
Patients elevated levels of urea and/or creatinine (renal impairment) presenting for 
work-up for a renal biopsy at Groote Schuur Hospital were identified by the nephrologist 
in the Renal Unit who informed the study investigators (from the Department of 
Anaesthesia) about potential candidates. Work-up for a renal biopsy included a referral 
to the Renal Unit, the biopsy could only be booked with the renal senior registrar and 
(as per the “criteria”) a BT was only performed if the creatinine was > 300 µmol/L. 
On the day of biopsy, the current protocol regarding haematological criteria for eligibility 
for a renal biopsy included (Addendum C): 
• A platelet count ≥ 100 x 109/L 
• PTT ˂ 40 seconds 
• INR ≤ 1.4 
• bleeding time ≤ 10 min, or ≤ 12 min if an emergency biopsy. 
These “criteria” are observed as a guideline only, with the final decision for or against 
proceeding with the biopsy made by the consultant nephrologist on the day of the 
biopsy. 
 
The TEG® and ROTEM® devices will be used as an alternative method of assessing the 
coagulation profile. This overcomes the technical difficulties of performing a bleeding 
time, as well as providing a more comprehensive in vitro assessment of coagulation. 
The primary outcome is thus to assess whole blood coagulation, using standard 
parameters generated by the TEG® and ROTEM® traces. In addition, fibrinogen 
concentrations (Wolberg & Campbell, 2008) will also be measured. 
 
A representative from the renal unit will inform the study group of patients on the day of 
the planned renal biopsy. Research participants will include both male and female adult 
subjects (age > 18) of any ethnicity with elevated levels of urea and/or creatinine 
presenting for a renal biopsy. These patients will be approached by a representative 
from the study group and included into the study only once informed consent 
(Addendum D) has been granted and prior to the provision of any sedation. Exclusion 
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criteria included patient refusal, LMWH/heparin therapy, antiplatelet medication and 
renal replacement therapy. 
 
Informed consent (Addendum D) was obtained on the day of the scheduled biopsy, prior 
to the provision of premedication. Blood sampling was standardised, blood being drawn 
using a Vacutainer (BD Vacutainer Systems, Plymouth, England). The initial blood draw 
of 3 mL was discarded, where after a whole-blood sample was collected in a 2 mL 
syringe and dispatched to the Department of Anaesthesia’s laboratory. A further 2 
samples were collected in two 4 mL Greiner 9 NC Coagulation Sodium Citrate 3.2% 
tubes (BD Vacutainer) – 1 sample being sent to the local laboratory (NHLS) for 
fibrinogen testing and the other sample to the study laboratory as a secondary sample. 
The TEG® was measured on the TEG® 5000 Thromboelastography Haemostasis 
Analyser System (Haemoscope) made available to us in the laboratory of the 
Department of Anaesthesia. ROTEM® was performed and analysed on the Viking 
ROTEM® Delta haemostasis analyser. The software for TEG® analysis was performed 
on TEG®V4.2.3. TEG® parameters included measurement of R-time (reaction time), K-
time (kinetics), maximum amplitude (MA) and coagulation index (CI) and was performed 
for each patient. 
 
ROTEM® was also performed for each patient as well, which included clotting time (CT), 
clot formation time (CFT), alpha (α) angle and maximum clot firmness (MCF). These 
additional tests included INTEM (essentially analysing the intrinsic pathway), EXTEM 
(analysing the extrinsic pathway), FIBTEM (the addition of a platelet inhibitor, which 
prevents platelets from contributing to thrombus formation thus allowing analyses of the 
functional fibrinogen component) and APTEM (addition of aprotinin to inhibit 
fibrinolysis). 
 
Both TEG® and ROTEM® were performed by the same laboratory technologist, to 
ensure standardisation of the tests. Ten staff members from the Department of 
Anaesthesia provided blood as a means of standardising quality control during the 
41 
 
study. All the results from the control samples fell within the specified ranges of the 
manufacturers. 
 
Statistical analysis was performed using a standard statistical package (Statistica 
Version 13, Dell Inc, Tulsa, OK) and data were evaluated in terms of means, medians, 
standard deviations and ranges. These measures were compared with the standard 
ranges for conventional tests, quoted by the instrument manufacturer, to identify 
possible coagulation abnormalities in this patient population (Pearson correlation). 
 
Results: 
A total of 44 adult participants was entered into this observational study. Results for 1 
participant (098/2013/26) were excluded from this study, as their biopsy was delayed 
which allowed their renal function to improve and return to normal, with medical 
management, on the day that they presented for a renal biopsy. 43 patients were 
worked up for a renal biopsy but only 38 patients proceeded to a renal biopsy. Of these, 
only 31 patients had a bleeding time performed (which should only be performed if 
creatinine ˃ 300 µmol/L as per the protocol) on the day of their renal biopsy. The age 
range of the participants in this study ranged from 24 to 69 years (with an average age 
of 41.3 years) and included 24 male and 19 female participants. Renal biopsies were 
cancelled by the consultant nephrologist in 5 patients for several reasons (Table 1: 
Cancellation of BiopsyTable 1) on the day of their biopsy. An interesting TEG® result 
was an average MA result of 74.22 mm (normal range 64 – 72 mm), which lies above 
the upper limit of normal. Two participants in the study developed a small renal 
haematoma on ultrasound after their biopsy (098/2013/26 was excluded from the 
study), with 1 of these patients also developing haematuria.  
All the results from the control samples, which comprised of 10 members from the 
Department of Anaesthesia, fell within the specified ranges of the various 
manufacturers. 
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Table 1: Cancellation of Biopsy 
Patient Reason for cancellation 
098/2013/19 The patient had a left mononephric, horseshoe kidney on U/S 
and biopsy was declined. 
098/2013/23 The biopsy was postponed on 2 occasions (first due to a low 
haemoglobin and then due to a prolonged bleeding time). The 
patient was then lost to follow-up. 
098/2013/36 The biopsy was postponed due to thrombocytopaenia. The 
patient deceased prior to the follow-up date. 
098/2013/40 The patient had bilateral echogenic kidneys and the biopsy was 
deemed unnecessary. 
098/2013/109 The patient was found to have a dilated cardiomyopathy with a 
poor ejection fraction (31%) and was rejected from further work-
up for the renal replacement programme. 
 
The normal range for the platelet count in the laboratory (NHLS) was 178 – 400 x 109/L. 
Of the 43 patients, the range for the platelet count was 95 – 863 x 109/l, with the 
average platelet count being 346.53 x 109/L. 
 
One fibrinogen level was not performed by the NHLS due to incorrect information being 
captured by the NHLS (laboratory error). This result was therefore discarded. Thus, only 
42 fibrinogen results were available for evaluation. The normal range for fibrinogen is 
2.0 – 4.0 g/dL. The range in the study was 1.4 – 6.0 g/dL, with the average being 3.61 
g/dL. There is no correlation between FIBTEM MCF and fibrinogen concentrations 
(Pearson’s correlation r = 0.12). 
 
The normal range for bleeding time is 2.30 – 9.50 min. Only 31 patients had bleeding 
times performed, as their creatinine levels exceeded the upper acceptable limit 
(creatinine ˃ 300 µmol/L). The average bleeding time for these 31 patients was 8.05 
min, with the range being 3.5 – 15.0 min. 
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The normal range for creatinine in the NHLS laboratory is 64 – 104 µmol/L. The average 
creatinine value was 607.84 µmol/L, with the range being 98 – 1486 µmol/L in our study 
population. 
 
The normal range for the R time is 4 - 8 min. The average R time was 7.13 min, with the 
range for the results being 1.8 – 11.9 min. 
 
The normal range for the K time is 0 - 4 min. The average K time was 1.62 min, with the 
range for the results being 0.8 – 4.4 min. 
 
The normal range for the Maximum Amplitude (MA) is 64 – 72 mm. The average MA 
was 74.22 mm (which lies above the upper limit of normal), with the range for the results 
being 36.5 – 87.9 mm. 
 
These results presented above are summarised in Table 2, with the full results sheet 
available as Addendum K in Part E: Supporting documents section. 
 
10 patients included in the study were diagnosed with End Stage Renal Disease 
(ESRD) after their biopsy, by the Department of Nephrology at Groote Schuur Hospital. 
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Table 2: Comparison of results with TEG® 
 Number of 
patients 
Normal range Average Range in study 
results 
Platelet count 
(units: x 109/L) 
43 178 – 400 346.53 95 – 863 
Fibrinogen 
(units: g/dL) 
42 2.0 – 4.0 3.61 1.4 – 6.0 
Bleeding time 
(units: min) 
31 2.30 – 9.50 8.05 3.5 – 15 
Urea 
(units: mmol/L) 
43 2.6 – 7.0 24.07 4.9 – 61.4 
Creatinine 
(units: µmol/L) 
43 64 – 104 607.84 98 – 1486 
R time  
(units: min) 
43 4 - 8  7.13 1.8 – 11.9 
K time 
(units: min) 
43 0 – 4 1.62 0.8 – 4.4 
MA 
(units: mm) 
43 54 – 72 74.22 36.5 – 87.9 
Alpha angle 
(units: degrees) 
43 47 – 74 69.2 36.5 – 81.0 
 
Table 3 summarises the results of the ROTEM® analysis. Of note, are the remarkable 
increases in the INTEM MCF, EXTEM MCF and FIBTEM MCF results, particularly in 
view of the absence of correlation between these results and the fibrinogen 
concentrations. 
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Table 3: Comparison of results with ROTEM® 
 Normal range Mean (SD) Above Range (n) Below Range (n) 
INTEM CT 
(units: s) 
100-240 158.8 (33.1) 0 1 
INTEM CFT 
(units: s) 
30 – 110 45.4 (29.5) 2 9 
INTEM MCF 
(units: mm) 
50 – 72 81.8 (2.9) 43 0 
EXTEM CT 
(units: s) 
38 – 79 74.2 (32.9) 12 0 
EXTEM CFT 
(units: s) 
34 – 159 47.3 (19.8) 0 5 
EXTEM MCF 
(units: mm) 
50 – 72 80.8 (3.5) 43 0 
FIBTEM MCF 
(units: mm) 
9 – 25 79.2 (5.3) 43 0 
 
Discussion: 
The performance of a renal biopsy remains a high-risk procedure and bleeding can 
have devastating consequences. It is essential to assess bleeding risk appropriately in 
these patients presenting for a renal biopsy. The exact coagulation disturbance in 
patients with renal impairment remains elusive. It has been proposed that the 
coagulopathy may be due to the consequences of elevated levels of urea on platelet 
function (Boccardo et al., 2004). Even though excessive post-surgical bleeding in 
patients with renal impairment is well documented (Berns & Coutre, 2015; Boccardo et 
al., 2004; Pivalizza, Abramson, & Harvey, 1997; Timmermans et al., 2009), there is also 
an associated increase in the incidence of thrombotic phenomena. In a study on 
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coagulation in uraemic patients using TEG® (Pivalizza et al., 1997), the group could 
demonstrate a hypercoagulable state in the TEG® indices. A study performed by 
Edwards, Morgan and Donnelly (1993) could also demonstrate hypercoagulability in 
uraemic patients using TEG® (Timmermans et al., 2009). The main finding of our study 
suggested a tendency towards a hypercoagulable state in many of the patients with 
elevated levels of urea and/or creatinine. The TEG® data showed that most patients had 
a normal onset of coagulation but that the MA and alpha angle both suggest a tendency 
towards hypercoagulation. The ROTEM® data showed a similar trend with both INTEM 
and EXTEM showing enhanced maximum clot firmness (MCF). The most interesting 
ROTEM® observation is the increase in the FIBTEM MCF (results for all participants 
were above the upper limit of normal). This is difficult to explain but possibly indicates 
that factor-based coagulation (as opposed to cell-based) is markedly enhanced in these 
patients. We could speculate that platelet function is normal or perhaps slightly 
diminished, but that factor-based coagulation is accelerated (possibly explained by the 
raised FIBTEM MCF). The mechanism for this may either be due to the fact that 
fibrinogen is an acute-phase protein whose activity is stimulated by the disease or that 
there is a relative lack of one of the inhibitory components, possibly antithrombin III. It is 
also possible that endothelium-derived thrombomodulin-driven regulation is impaired, 
but this is not examined in ex-vivo studies such as this study. Whatever the mechanism, 
the finding is very interesting given the problems that the renal dialysis teams 
experience with thrombosis of arterio-venous shunts. Analyses of the standard 
coagulation data, on average, fall within normal limits. Average fibrinogen levels were 
noted to be normal to only slightly elevated (Addendum L). However, several patients in 
our study (16 out of 42 participants with fibrinogen results) had elevated fibrinogen 
levels. A further interesting observation from the standard coagulation tests is that there 
is a weak, non-significant, correlation between rising creatinine and platelet count 
(Addendum M) and a somewhat stronger, significant correlation between creatinine and 
bleeding time (Addendum N). This helps to explain the rather confusing paradox that is 
so widely reported in patients with renal failure, that although they may demonstrate a 
bleeding tendency, they may also be at increased risk of venous thrombosis. Several 
limitations of this study are identified. The lack of a comparison group with 
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randomisation to compare visco-elastic testing to conventional tests of coagulation. This 
study was purely observational, and the biopsy only proceeded if the consultant 
nephrologist on duty on the day of biopsy deemed that the biopsy was necessary. The 
functioning of platelets in patients with renal failure needs to be further assessed with 
some form of platelet function analyser – a subject for future research. 
 
Conclusion: 
This prospective observational study of patients with elevated levels of urea and/or 
creatinine presenting for renal biopsy demonstrated that the coagulation status as 
depicted by visco-elastic tests revealed no evidence of bleeding risk and tends to 
suggest that large numbers of these patients are, in fact, hypercoagulable as almost 
70% of the participants in this study had a maximum amplitude above the upper limit of 
normal. This was further substantiated by the elevation in fibrinogen levels and the 
enhanced fibrinogen contribution to coagulation as illustrated by the ROTEM® results, 
although the absence of significant correlation between these results tends to argue 
against a cause-and-effect phenomenon. 
The strengths of this study are that conventional testing and visco-elastic testing were 
analysed side-by-side in an observational manner. The patients were followed up for 
bleeding complications post procedure. The incidence of bleeding post renal biopsy was 
considered low (2 out of 38 patients developed a haematoma); however, this 
complication would be unacceptable in patients receiving regional or neuraxial 
techniques. Conventional bleeding times showed no correlation with visco-elastic 
testing. The overall finding was that the coagulation profile of patients with renal failure 
showed a normal distribution using visco-elastic testing. The fibrinogen levels were 
surprisingly normal to slightly elevated in the entire cohort which underpins the 
enhanced coagulation seen in these patients (Addendum L). 
This pilot study is firmly hypothesis generating and paves the way for a comparative trial 
to evaluate conventional tests of coagulation and the visco-elastic tests to evaluate 
bleeding and/or the bleeding risk in patients with impaired renal function. There were no 
notable serious haemorrhagic complications post-biopsy in the patient group, who 
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participated in this study, when they presented for their renal biopsy. The normal to 
elevated fibrinogen levels noted in some of the participants - could possibly account for 
the enhanced coagulation profile seen in some participants in this study. Platelet 
function is of concern in these patients but unless fibrinogen levels are low, the findings 
from this pilot study suggest that coagulation may not be affected. 
 
Ethical considerations: 
The study was approved by the Ethics Committee of the Faculty of Health Sciences of 
the University of Cape Town (Addendum B). 
Participation in the study was voluntary, and participants completed an informed 
consent form (Addendum D). 
Participants received a participant number and could only be further identified 
throughout the study with the participant number ensuring confidentiality and anonymity. 
All data was stored under the participant number (Addendum E and Addendum F). 
Participants could withdraw at any time and without providing a reason. 
All patients continued to receive the normal standard of care, irrespective of 
participation or non-participation in the study (Addendum C). 
Participants were assured that they would be at no extra risk if they agreed to 
participate in the study. 
Participants received no direct benefit from participation in the study but participation 
neither hindered nor changed the standard of care they received. 
There was no cost, nor compensation for participation in the study. 
No conflicts of interest were identified or declared. 
The protocol complied with the Helsinki Declaration of 2008. 
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Addendum L: Fibrinogen graph 
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Addendum M: Creatinine vs Platelets graph 
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Addendum N: Creatinine vs Bleeding Time graph 
 
 
 
